[Pharmacokinetics of fenofibrate in man (author's transl)].
The active metabolite of fenofibrate is fenofibric acid, which is strongly bound to serum proteins. Following a single oral dose of 300 mg fenofibrate there is a diphasic decrease in plasma levels of fenofibric acid, and most of the drug is excreted as conjugate in the urine. Following daily oral administration of 300 mg during 10 days, a state of equilibrium is obtained within 2 to 3 days and persists throughout the observation period; the mean elimination half-life and urinary excretion rate are very similar to those measured after a single dose, and the drug does not accumulate. In patients with renal insufficiency, the plasma half-life of fenofibric acid is very substantially prolonged and considerable accumulation takes place, as the compound is virtually not dialyzable. Doses of 100 mg/day produce plasma levels similar to those obtained with 300 mg/day. The lipid-lowering activity mostly affects triglycerides. Concomitant administration of colestipol has no effect on blood kinetics and urinary excretion of fenofibrate but results in very important reduction of all lipoprotein fractions.
D003084:Colestipol / Q000378:metabolism / Q000627:therapeutic use; D004347:Drug Interactions; D011345:Fenofibrate / Q000008:administration & dosage / Q000378:metabolism* / Q000627:therapeutic use; D006207:Half-Life; D006801:Humans; D006949:Hyperlipidemias / Q000188:drug therapy; D000960:Hypolipidemic Agents / Q000008:administration & dosage / Q000378:metabolism* / Q000627:therapeutic use; D007674:Kidney Diseases / Q000378:metabolism; D007700:Kinetics; D011422:Propionates / Q000378:metabolism*
D000960:Hypolipidemic Agents; D011422:Propionates; D003084:Colestipol; D011345:Fenofibrate
Pharmacocinétique du fénofibrate chez l'homme.